Carregant...
Pharmacogenomic considerations for repurposing of dexamethasone as a potential drug against SARS-CoV-2 infection
Immunomodulatory and analgesic effects of dexamethasone are clinically well established, and this synthetic corticosteroid acts as an agonist of glucocorticoid receptors. Early results of the RECOVERY Trial from the United Kingdom and others suggest certain benefits of dexamethasone against COVID-19...
Guardat en:
| Publicat a: | Per Med |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Future Medicine Ltd
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8186476/ https://ncbi.nlm.nih.gov/pubmed/34086487 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/pme-2020-0183 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|